尿液蛋白激酶Y基因启动子位点甲基化在前列腺癌早期诊断中的价值  

The value of urine protein kinase Y⁃linked gene promoter site methylation in early diagnosis of prostate cancer

作　　者：刘伟峰 戴政 周毅彬[1] 封凯文 魏恺 孙古乐 阳东荣[1] 朱进[1] LIU Weifeng;DAI Zheng;ZHOU Yibin;FENG Kaiwen;WEI Kai;SUN Gule;YANG Dongrong;ZHU Jin(Department of Urology,the Second Affiliated Hospital of Soochow University,Suzhou 215004,China;不详)

机构地区：[1]苏州大学附属第二医院泌尿外科,江苏苏州215004 [2]安徽医科大学第三附属医院(合肥市第一人民医院)泌尿外科,合肥230001

出　　处：《实用医学杂志》2024年第5期688-694,共7页The Journal of Practical Medicine

基　　金：国家自然科学基金项目(编号:81773221);苏州市姑苏卫生人才科研项目(编号:GSWS2021016);苏州市科技计划项目(编号:SS201857)。

摘　　要：目的 探讨尿液蛋白激酶(PRKY)基因启动子位点甲基化在前列腺癌(PCa)早期诊断中的临床价值。方法 收集50例疑似PCa患者的尿液,提取DNA后,通过定量甲基化特异性PCR(qMSP)法检测PRKY基因启动子位点cg05163709、cg08045599及cg05618150甲基化水平,同时将患者分为良性前列腺增生(BPH)组和PCa组,并分析两组患者临床指标差异以及两组患者尿液中的PRKY基因启动子位点甲基化状态。建立受试者工作特征曲线(ROC),计算曲线下面积(AUC),分析其在PCa中的诊断价值,并联合临床指标进行联合诊断。结果 PCa患者尿液标本中cg05163709和cg05618150甲基化率明显高于BPH患者,其中cg05163709甲基化诊断PCa的AUC为0.762,敏感度为86.70%。与前列腺特异性抗原(tPSA)等临床指标相比,PRKY甲基化在PCa早期筛查中表现更好。cg05618150甲基化与前列腺特异抗原密度(PSAD)联合诊断的AUC为0.787,敏感度为86.70%;cg05163709甲基化与PSAD联合诊断PCa的AUC为0.855,特异度为95.00%。结论 尿液PRKY基因启动子cg05163709和cg05618150位点甲基化在诊断PCa上具有较高的敏感度和特异度,有望成为PCa早期诊断的生物标志物。Objective To explore the clinical value of methylation at promoter sites of urine protein kinase Y-linked(PRKY)gene in the early diagnosis of prostate cancer(PCa).Methods Urine samples were collected from 50 suspected PCa patients.After extracting DNA,the methylation levels of the PRKY gene promoter sites cg05163709,cg08045599,and cg05618150 were detected using quantitative methylation-specific PCR(qMSP).Simultaneously,the patients were divided into the benign prostatic hyperplasia(BPH)group and the PCa group.The differences in clinical indicators between the two groups were analyzed,as well as the methylation status of the PRKY gene promoter sites in the urine of the two groups of patients.The receiver operating charac-teristic(ROC)curve of PRKY promoter sites methylation was established,and the area under the curve(AUC)was calculated to analyze the diagnostic value of PRKY promoter sites methylation in PCa,and to perform com-bined diagnosis with clinical indicators.Results The methylation rates of cg05163709 and cg05618150 in urine specimens of PCa patients were significantly higher than those of BPH patients.The AUC for cg05163709 methyla-tion in diagnosing PCa was 0.762,with a sensitivity of 86.70%.It showed better performance in early screening for PCa compared to total prostate specific antigen(tPSA),percentage free prostate specific antigen(f/tPSA)and prostate specific antigen density(PSAD)index.We found that the AUC for cg05618150 methylation in conjunc-tion with PSAD in diagnosing PCa was 0.787,with a sensitivity of 86.70%.The AUC of cg05163709 methylation and PSAD in the joint diagnosis of PCa was 0.855,and the specificity could reach 95.00%.Conclusion The methylation of urine PRKY gene promoter sites cg05163709 and cg05618150 shows high sensitivity and specificity in diagnosing PCa,making them promising biomarkers for early detection of PCa.

关 键 词：前列腺癌 尿液蛋白激酶Y 早期诊断 甲基化 临床价值 

分 类 号：R737.25[医药卫生—肿瘤]